Hatchtech locks in new funding for lead project
This article was originally published in Scrip
Executive Summary
Hatchtech has overcome the difficult markets to secure A$2.5million ($1.7 million) in new venture capital, which it will use to take its lead development project, a prescription treatment for head lice, into Phase II trials.